EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische StudieOpen Access · CC BY-NC-ND 4.0

One-year outcomes from the pivotal trial of a four-branch off-the-shelf solution to treat pararenal and extent IV thoracoabdominal aortic aneurysms

Mark A Farber, Sukgu Han, Michel S Makaroun, Jon S Matsumura, Bernardo C Mendes, Gustavo S Oderich, Luis A Sanchez, Bjoern D Suckow, Carlos H Timaran

Journal of Vascular Surgery · 2025

DOI: 10.1016/j.jvs.2025.05.016 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Vascular Surgery, 2025. Verfasst von Mark A Farber und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Vascular Surgery, Department of Surgery, University of North Carolina, Chapel Hill, NC. Electronic address: mark_farber@med.unc.edu. Hauptthemen laut MEDLINE: Aortic Aneurysm, Thoracic, Endovascular Procedures, Blood Vessel Prosthesis, Blood Vessel Prosthesis Implantation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: W L Gore & Associates Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To report 1-year primary-arm outcomes of the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis pivotal trial. METHODS: The multicenter, nonrandomized, prospective study included patients with extent IV thoracoabdominal aortic aneurysms (TAAAs) and pararenal aortic aneurysms (PRAAs). All-cause and adjudicated lesion-related mortality were assessed at 12 months. Core-lab-reported, imaging-dependent outcomes included aneurysm size, endoleaks assessed through 1-year follow-up window, and target vessel instability (defined as occlusion, stenosis, type Ic/IIIc endoleak, or reintervention) at 1 year. RESULTS: One hundred two patients were treated; 59 patients had an extent IV TAAA and 43 had a PRAA. The mean maximum aneurysm diameter was 59.4 ± 7.8 mm. At 1 year, eight patients were lost to follow-up and six patients died (1 device-related, 1 procedure-related, and 4 unrelated causes). No lesion-related mortality occurred. Freedom from all-cause mortality was 94.1% ± 2.3%. The 1-year combined freedom from "clinically significant reintervention" and lesion-related mortality was achieved in 78.7% and 60.5% of patients with extent IV TAAAs and PRAAs, respectively (P = .09). At least one target vessel branch occlusion occurred in 14.7% of patients through 1 year of follow-up. At the vessel level, freedom from target vessel instability at 1 year was 94.2% ± 1.2% (celiac 99.0% ± 1.0%, superior mesenteric 97.1% ± 1.7%, right renal 90.8% ± 2.9%, and left renal 89.8% ± 3.1%). Acute kidney injury requiring dialysis occurred in three patients (n = 2 permanent, n = 1 temporary) through 1 year. Renal artery occlusion occurred more often in arteries with diameters 5 mm) occurred in 5 patients (6.0%). Aneurysm shrinkage (>5 mm) occurred in 20 patients (23.8%). Aortic component fractures identified in 3 patients (3.6%) were clinically insignificant. CONCLUSIONS: Although mortality remains low 1 year after treatment with the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis device for extent IV and pararenal aneurysms, renal artery occlusion was the predominant adverse event and was primarily associated with PRAAs and smaller renal vessel diameters. During extended follow-up, attention should be focused on renal branch assessment to identify patients at risk for occlusion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aortic Aneurysm, ThoracicEndovascular ProceduresBlood Vessel ProsthesisBlood Vessel Prosthesis ImplantationStentsAortic Aneurysm, AbdominalHumansMaleFemaleAgedTime FactorsProspective StudiesProsthesis DesignRisk FactorsMiddle AgedTreatment OutcomeAged, 80 and overEndoleakPostoperative ComplicationsUnited StatesAortic Aneurysm, Thoracoabdominal

Stichwörter der Autor:innen

AneurysmEndovascular graftingEndovascular interventionsEndovascular repairPara-supra renalTarget vessel instabilityThoracic/thoracoabdominal

Autor:innen und Institutionen

  • Division of Vascular Surgery, Department of Surgery, University of North Carolina, Chapel Hill, NC. Electronic address: mark_farber@med.unc.edu.
  • Division of Vascular Surgery and Endovascular Therapy, Keck Medical Center of University of Southern California, Los Angeles, CA.
  • Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.
  • Division of Vascular Surgery, University of Colorado School of Medicine, Aurora, CO.
  • Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, MN.
  • Division of Vascular Surgery and Endovascular Therapy, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX.

Förderung

  • W L Gore & Associates Inc

Zitieren

APA

Farber, M. A., Han, S., Makaroun, M. S., Matsumura, J. S., Mendes, B. C., Oderich, G. S., Sanchez, L. A., Suckow, B. D., & Timaran, C. H. (2025). One-year outcomes from the pivotal trial of a four-branch off-the-shelf solution to treat pararenal and extent IV thoracoabdominal aortic aneurysms. Journal of Vascular Surgery. https://doi.org/10.1016/j.jvs.2025.05.016

Vancouver

Farber MA, Han S, Makaroun MS, Matsumura JS, Mendes BC, Oderich GS, et al. One-year outcomes from the pivotal trial of a four-branch off-the-shelf solution to treat pararenal and extent IV thoracoabdominal aortic aneurysms. Journal of Vascular Surgery. 2025. doi:10.1016/j.jvs.2025.05.016

BibTeX
@article{Farber2025,
  author = {Farber, Mark A and Han, Sukgu and Makaroun, Michel S and Matsumura, Jon S and Mendes, Bernardo C and Oderich, Gustavo S and Sanchez, Luis A and Suckow, Bjoern D and Timaran, Carlos H},
  title = {One-year outcomes from the pivotal trial of a four-branch off-the-shelf solution to treat pararenal and extent IV thoracoabdominal aortic aneurysms},
  journal = {Journal of Vascular Surgery},
  year = {2025},
  doi = {10.1016/j.jvs.2025.05.016}
}
Kostenlos starten →